Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 1997

View Archived Issues

Endorex licenses anticancer drug perillyl alcohol

Pfizer enters phase I trials with CP-358774

Stanford announces three studies on leg ischemia treatments

NIH announces discovery of new breast cancer gene

Glucose metabolism gene related to longevity

Palatin meets with FDA on LeuTech

Genetic Evolutionary Nutrition licenses pyruvate

Viazem approved in 10 European countries

DiagnoCure acquires NASBA technology application rights

Gene affecting neurodegeneration cloned

Kinetin clinical data to be presented at IBC symposium

Oxis granted patent application allowance for ergothioneine analogs

Salagen approved for Sjogren's syndrome in Canada

Repaglinide gets expedited review status in U.S

DPP-IV inhibition in the treatment of diabetes

Digestive tract marker evaluated in diabetic patients with gastroenteropathies

Imidazoline derivative displays potent antidiabetic effects in rats

Antidiabetic herbomineral formulation tested in Indian patients

Rapid-acting insulin analog under clinical evaluation

Boston Life Sciences completes phase III trial of Therafectin

EntreMed: Q2 1997 highlights

Merck KGaA begins development of cardioprotectant

Antimigraine agent in pharmacokinetic testing at HMR

GT35 described in patent literature by Kyowa Hakko

Fibrinogen antagonists from Yamanouchi

New antiallergy agents described by Dainippon Ink

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...